Finch Therapeutics Group Stock Shares Owned By Insiders
| FNCHDelisted Stock | USD 8.51 0.19 2.18% |
Finch Therapeutics Group fundamentals help investors to digest information that contributes to Finch Therapeutics' financial success or failures. It also enables traders to predict the movement of Finch Pink Sheet. The fundamental analysis module provides a way to measure Finch Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Finch Therapeutics pink sheet.
Finch |
Finch Therapeutics Group Company Shares Owned By Insiders Analysis
Finch Therapeutics' Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current Finch Therapeutics Shares Owned By Insiders | 53.48 % |
Most of Finch Therapeutics' fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Finch Therapeutics Group is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
CompetitionBased on the latest financial disclosure, 53% of Finch Therapeutics Group are shares owned by insiders. This is 252.31% higher than that of the Biotechnology sector and 277.15% higher than that of the Health Care industry. The shares owned by insiders for all United States stocks is notably lower than that of the firm.
Finch Shares Owned By Insiders Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Finch Therapeutics' direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Finch Therapeutics could also be used in its relative valuation, which is a method of valuing Finch Therapeutics by comparing valuation metrics of similar companies.Finch Therapeutics is currently under evaluation in shares owned by insiders category among its peers.
Finch Fundamentals
| Return On Equity | -0.63 | ||||
| Return On Asset | -0.22 | ||||
| Current Valuation | 10.74 M | ||||
| Shares Outstanding | 1.61 M | ||||
| Shares Owned By Insiders | 53.48 % | ||||
| Shares Owned By Institutions | 11.35 % | ||||
| Number Of Shares Shorted | 19.2 K | ||||
| Price To Book | 0.14 X | ||||
| Price To Sales | 30.46 X | ||||
| Revenue | 107 K | ||||
| Gross Profit | (57.03 M) | ||||
| EBITDA | (32.48 M) | ||||
| Net Income | (74.75 M) | ||||
| Cash And Equivalents | 104.67 M | ||||
| Cash Per Share | 2.19 X | ||||
| Total Debt | 30.13 M | ||||
| Debt To Equity | 0.35 % | ||||
| Current Ratio | 7.28 X | ||||
| Book Value Per Share | 11.86 X | ||||
| Cash Flow From Operations | (31.5 M) | ||||
| Short Ratio | 0.19 X | ||||
| Earnings Per Share | (6.59) X | ||||
| Price To Earnings To Growth | (0.02) X | ||||
| Target Price | 90.0 | ||||
| Beta | 0.46 | ||||
| Market Capitalization | 1.94 M | ||||
| Total Asset | 71 M | ||||
| Retained Earnings | (350.39 M) | ||||
| Working Capital | 21.76 M | ||||
| Net Asset | 71 M |
About Finch Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Finch Therapeutics Group's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Finch Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Finch Therapeutics Group based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Other Consideration for investing in Finch Pink Sheet
If you are still planning to invest in Finch Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Finch Therapeutics' history and understand the potential risks before investing.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |